Thiourea derivatives induce fetal hemoglobin production in-vitro: A new class of potential therapeutic agents for β-thalassemia
| Autor: | Hamad Ali, Sarah Shafi, Hina Siddiqui, Ishtiaq Ahmad Khan, Syed Ghulam Musharraf, Fizza Iftikhar, M. Iqbal Choudhary |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
congenital hereditary and neonatal diseases and abnormalities Cell Survival Thalassemia Pharmacology Flow cytometry 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Erythroid Cells hemic and lymphatic diseases Fetal hemoglobin medicine Cytotoxic T cell Humans Fetal Hemoglobin Cell Proliferation medicine.diagnostic_test beta-Thalassemia Thiourea Cell Differentiation medicine.disease In vitro Sickle cell anemia Benzidine 030104 developmental biology chemistry Gene Expression Regulation K562 Cells 030217 neurology & neurosurgery |
| Zdroj: | European journal of pharmacology. 855 |
| ISSN: | 1879-0712 |
| Popis: | Fetal hemoglobin (HbF) induction is a cost-effective therapeutic approach for the treatment of β-hemoglobinopathies like β-thalassemia and sickle cell anemia. The present study discusses the potential of thiourea derivatives as new class of compounds that induce the fetal hemoglobin production. HbF inducing effect of thiourea derivatives was studied using experimental cell system, the human erythroleukemic K562 cell line. Erythroid induction of K562 cells was studied by the benzidine/H2O2 reaction, total hemoglobin production was estimated by plasma hemoglobin assay kit, and γ-globin gene expression by RT-qPCR, whereas fetal hemoglobin production was estimated by flow cytometry and immunofluorescence microscopy. The results indicated that newly synthesized thiourea derivative are potent inducers of erythroid differentiation of K562 cells with an increased γ-globin gene expression and fetal hemoglobin production. Moreover, these compounds showed no cytotoxic effect and inhibition on K562 cells at HbF inducing concentrations. It is important to note that hydroxyurea is a cytotoxic chemotherapeutic agent and have deleterious side effects, reflecting the need to identify new safe and effective HbF induces. These results signify thiourea derivatives as promising HbF inducers, with the potential to be studied against hematological disorders, including β-thalassemia and sickle cell anemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect